Compare Vistra Corp (VST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vistra Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Vistra Corp trades at $151.01 (market cap $50.11B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: Vistra Corp pays a 0.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vistra Corp nearer its low. Which is the better fit depends on your goals.
| VST | XBI | |
|---|---|---|
Market Cap | $50.11B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $217.92 | $169.55 |
52-Week Low | $134.71 | $93.43 |
Enterprise Value | $72.05B | — |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vistra Corp. (VST) trades at $151.72, up 1.62% today, with a bullish technical signal and strong analyst support. The stock shows mixed quarterly earnings but projects significant revenue and net income growth into 2026. Recent news highlights CEO and institutional buying, long-term power agreements with tech giants, and a consensus price target of $228.40, suggesting substantial upside potential from current levels.
The outlook is positive, driven by robust power demand, strategic partnerships, and a diversified generation fleet. Key risks include regulatory uncertainty and earnings volatility. With 91% of analysts rating it a buy and insider confidence, VST presents a compelling opportunity for growth-oriented investors, though market fluctuations and execution risks warrant caution.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
